CSC
TTNP

Caldwell Sutter Capital’s Titan Pharmaceuticals TTNP Stock Holding History

Caldwell Sutter Capital’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1 Hold
1
– – ﹤0.01% 927
2026
Q1 		$1 Hold
1
– – ﹤0.01% 889
2025
Q4 		$2 Hold
1
– – ﹤0.01% 874
2025
Q3 		$5 Hold
1
– – ﹤0.01% 863
2025
Q2 		$4 Hold
1
– – ﹤0.01% 849
2025
Q1 		$4 Hold
1
– – ﹤0.01% 883
2024
Q4 		$3 Hold
1
– – ﹤0.01% 894
2024
Q3 		$5 Hold
1
– – ﹤0.01% 903
2024
Q2 		$6 Hold
1
– – ﹤0.01% 916
2024
Q1 		$7 Buy
+1
New +$7 ﹤0.01% 912
2023
Q4 		– Hold
0
– – – 953
2023
Q3 		– Hold
0
– – – 887
2023
Q2 		– Hold
0
– – – 862
2023
Q1 		– Hold
0
– – – 564
2022
Q4 		– Hold
0
– – – 315

Other funds holding TTNP

CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
BWL
Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Caldwell Sutter Capital's TTNP Position: Q2 2026 in Review

Caldwell Sutter Capital held its Titan Pharmaceuticals (TTNP) position steady in Q2 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #927.

Caldwell Sutter Capital first reported a position in TTNP in Q1 2024 and has held it in 10 quarters since. The position peaked at $7 in Q1 2024. 5 funds tracked by Wall St. Rank hold TTNP as of Q2 2026.

  • Caldwell Sutter Capital held 1 share of Titan Pharmaceuticals worth $1 as of Q2 2026.
  • Caldwell Sutter Capital left its Titan Pharmaceuticals share count unchanged in Q2 2026.
  • Titan Pharmaceuticals made up ﹤0.01% of Caldwell Sutter Capital's portfolio in Q2 2026, its #927 holding.
  • Caldwell Sutter Capital first reported a position in Titan Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Caldwell Sutter Capital's Titan Pharmaceuticals position peaked at $7 in Q1 2024.
  • 5 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2026.

Based on Caldwell Sutter Capital's 13F filing for Q2 2026, filed 5 Aug 2026.